GLIMPSE ON PHARMACOGENOMICS
From DawaSpace.
Pharmacogenomics is the study of how differences in genetic factors in different individuals affect their response to drugs. It was commonly understood that our genetic factors play a role in how we respond to drugs, but the fact that the variations in genetic factors among individual could affect how we respond to drugs was yet to be established. The Pharmacogenetics field began when certain individual who had genetic variation in enzyme responsible for metabolizing drugs experienced abnormally severe drug reaction.
The
sequencing of human genome has contributed a lot to the development of this
study. In 1957 the geneticist Arno Motulsky Published an article that highlighted the evidence that the antimalaria
drug primaquine and the muscle relaxant suxamethonium
chloride, possessed the
adverse drug reactions that were heritable and linked to deficit in specific
enzymes.
Below are the scenarios in which Pharmacogenomics study is evident and applicable
Abacavir hypersensitivity reactions
Abacavir is a nucleoside reverse transcriptase Inhibitor , a anti-retroviral drug indicated for the treatment of human immune deficiency virus (HIV) infections, abacavir is used as the part of multi drug combination in Highly active Anti Retro viral therapy (HAART), data shows that 5% of patients on abacavir experience severe hypersensitivity reaction to the drug, it has been established that the reactions experienced by these patients is due to variations on the gene HLA -B in which patient experiencing these reactions possessed HLA -B*57:01.The signs and symptoms of abacavir hypersensitivity reaction includes rashes ,fever, nausea, vomiting ,diarrhea, abdominal pain , Malaise, dyspnea, cough and Pharyngitis ,it is now recommended that the newly HIV diagnosed patient be tested for HLA-B gene to establish whether or not they will be suitable candidate for abacavir.
Thiopurines
toxicity
The drugs in thiopurine group includes azathioprine, mercaptopurines, and thioguanine, these drugs are clinically indicated in treatment of certain types of leukemia, auto immune disorder, and inflammatory bowel diseases. Thiopurines methyl transferases (TPMT) is the enzyme responsible for metabolism of these drugs. Certain individual have deficiency in thiopurine methyl transferase enzymes due to gene mutation, it is approximated that 1 in 300 individuals possess this deficient. The Presence of fewer enzyme responsible for metabolizing these drugs expose the patient to toxic effect of these drug even when given under normal dose, because a significant amount of dose remains unchanged in the system.
The drugs found in this group include 5-Flouro uracil and its oral pro
drug Capecitabine, these drug are mainly used in treatment of solid tumors such
as head and neck , gastrointestinal and breast cancer. The major cause of fluoropyridines
toxicity is the deficiency of the enzyme Dihydropyridine dehydrogenase (DPD),
The enzyme dihydropyridine dehydrogenase is responsible for breaking down the frouropyrimidine,
(5-FU and capecitabine). The DPD deficiency is caused by variants in the
dihydropyridine dehydrogenase (DPYD) gene, which are associated with an
increased risk of severe, specific side effects in carriers. About 30% of 5-Fu toxicity is
linked to deficiency of DPD enzyme however other factors also plays a role in
toxicity of this drug.
Irinotecan toxicity
Irinotecan is an antineoplastic drug clinically indicated for treatment
of various form of neoplasm which includes ,metastatic colorectal cancer, non-small
cell lung cancer and Ovarian cancer .This drug has the potential of causing
severe side effects which ranges from severe diarrhea to neutropenia,
some patients taking irinotecan experience severe and life threatening side
effects when compared to other patients
,this is the result of genetic differences that exists in enzymes responsible
for metabolism of this drug, irinotecan being a pro drug is metabolized into
the active form SN-38 by the enzyme
carboxylesterases 1 and 2 ,the active metabolite SN-38 is responsible for the
majority therapeutic actions of the drug also its toxicity is related to this
metabolite. Some individual’s posses’ genes that cause reduced or total loss of
function to the enzyme responsible for inactivation of this metabolite, the
metabolite SN-38 remains active for long time in these individuals leading to
severe adverse effects.
Warfarin Toxicity
Warfarin is one of the earliest known oral anticoagulants that function as vitamin K antagonist. Metabolism of warfarin occurs through CYP2C9 enzymes, Vitamin K epoxide reductase complex subunit 1 (VKORC1), encoded by the VKORC1 gene is the target of anticoagulant warfarin and a key enzyme in the vitamin K recycling .The pharmacologic action of warfarin is mediated through inactivation of VKORC1, and since the discovery of the VKORC1 gene in 2004, numerous studies have indicated that individuals with decreased VKORC1 expression, are at increased risk for excessive anticoagulation following standard warfarin dosages. Furthermore, warfarin is administered as a racemic mixture of R- and S-warfarin, and patients with reduced-function CYP2C9 genotypes are at increased risk for bleeding due to decreased metabolic clearance of the more potent S-warfarin enantiomer. It is predicted that gene-based dosing may help optimize warfarin therapy management and minimize risks for adverse drug reactions
Comments
Post a Comment